Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M245Revenue $M10.3Net Margin (%)-161.9Z-Score9.9
Enterprise Value $M218EPS $-0.6Operating Margin %-162.6F-Score5
P/E(ttm))0Cash Flow Per Share $1.4Pre-tax Margin (%)-161.9Higher ROA y-yY
Price/Book10.910-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsY
Price/Sales15.25-y EBITDA Growth Rate %0Current Ratio3.1Lower Leverage y-yY
Price/Cash Flow3.6y-y EBITDA Growth Rate %0ROA % (ttm)-47.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-93.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M30.9ROI % (ttm)-25.4Gross Margin Increase y-yN

Gurus Latest Trades with POZN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

POZN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


POZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BARNHARDT JOHN EVP, Finance and Administration 2014-08-11Sell18,100$8.25-6.42 view
PLACHETKA JOHN RPresident, CEO and Chairman 2014-08-08Sell50,000$7.75-0.39 view
PLACHETKA JOHN RPresident, CEO and Chairman 2014-07-30Sell50,000$7.345.18 view
PLACHETKA JOHN RPresident, CEO and Chairman 2014-07-09Sell50,000$8.88-13.06 view
Hodges William LSr. VP Finance, CFO 2014-07-02Sell11,414$9.05-14.7 view
Hodges William LSr. VP Finance, CFO 2014-06-23Sell5,688$9.05-14.7 view
BARNHARDT JOHN EVP, Finance and Administration 2014-06-23Sell27,484$8.8-12.27 view
Hodges William LSr. VP Finance, CFO 2014-06-20Sell50,000$9.05-14.7 view
Hodges William LSr. VP Finance, CFO 2014-06-19Sell9,516$9.05-14.7 view
Hodges William LSr. VP Finance, CFO 2014-06-17Sell112,156$9.03-14.51 view

Press Releases about POZN :

Quarterly/Annual Reports about POZN:

News about POZN:

Articles On GuruFocus.com
Weekly Insider Sells Highlight: AR, CSCO, SUTR, POZN, JAH May 27 2014 
Guru Weekly Real Time Update Jul 12 2013 
John Rogers Makes 5 Real-Time Increases Jul 11 2013 
John Rogers' May Commentary - What's Attractive and New Buys Jun 13 2013 
comment on POZN Nov 13 2012 
Pozen Inc. Reports Operating Results (10-K) Mar 10 2011 
Pozen Inc. Reports Operating Results (10-Q) Oct 29 2010 
Pozen Inc. Reports Operating Results (10-Q) Aug 05 2010 
Pozen Inc. Reports Operating Results (10-Q) Apr 29 2010 
Pozen Inc. Reports Operating Results (10-Q) Nov 02 2009 

More From Other Websites
Nasdaq stocks posting largest percentage increases Aug 20 2014
POZEN Announces U.S. Rights For TREXIMET® Have Been Acquired by Pernix Therapeutics Aug 20 2014
POZEN INC /NC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 20 2014
8:01 am POZEN announces U.S. rights For TREXIMET have been acquired by Pernix Therapeutics (Aug 20 2014
POZEN Announces U.S. Rights For TREXIMET® Have Been Acquired by Pernix Therapeutics Aug 20 2014
POZEN INC /NC Financials Aug 19 2014
Horizon Pharma Announces U.S. Patent and Trademark Office Issuance of an Additional Notice of... Aug 13 2014
POZN: Solid Second Quarter Financial Results Keep Us Bullish On Pozen Aug 07 2014
POZEN Reports Second Quarter 2014 Results Aug 07 2014
Pozen Inc Earnings Call scheduled for 11:00 am ET today Aug 07 2014
POZEN INC /NC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
POZEN Reports Second Quarter 2014 Results Aug 07 2014
Q2 2014 POZEN Inc. Earnings Release - Before Market Open Aug 07 2014
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of... Aug 05 2014
POZEN Announces August 7th Webcast of Second Quarter 2014 Results Jul 24 2014
POZEN Announces August 7th Webcast of Second Quarter 2014 Results Jul 24 2014
Why POZEN (POZN) Stock Is Tanking Today Jul 16 2014
POZEN Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 Tablets Jul 16 2014
POZEN INC /NC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 16 2014
POZEN Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 Tablets Jul 16 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide